A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. / Sigalet, David L; Kravarusic, Dragan; Butzner, Decker; Hartmann, Bolette; Holst, Jens Juul; Meddings, Jon.

I: Canadian Journal of Gastroenterology, Bind 27, Nr. 10, 10.2013, s. 587-92.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sigalet, DL, Kravarusic, D, Butzner, D, Hartmann, B, Holst, JJ & Meddings, J 2013, 'A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients', Canadian Journal of Gastroenterology, bind 27, nr. 10, s. 587-92. <http://www.ncbi.nlm.nih.gov/pubmed/24106731>

APA

Sigalet, D. L., Kravarusic, D., Butzner, D., Hartmann, B., Holst, J. J., & Meddings, J. (2013). A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. Canadian Journal of Gastroenterology, 27(10), 587-92. http://www.ncbi.nlm.nih.gov/pubmed/24106731

Vancouver

Sigalet DL, Kravarusic D, Butzner D, Hartmann B, Holst JJ, Meddings J. A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. Canadian Journal of Gastroenterology. 2013 okt;27(10):587-92.

Author

Sigalet, David L ; Kravarusic, Dragan ; Butzner, Decker ; Hartmann, Bolette ; Holst, Jens Juul ; Meddings, Jon. / A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. I: Canadian Journal of Gastroenterology. 2013 ; Bind 27, Nr. 10. s. 587-92.

Bibtex

@article{8a17ab8315804dcfabaa0c3ed7ab21f8,
title = "A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients",
abstract = " BACKGROUND⁄/OBJECTIVES: The relationship between the enteroendocrine hormone glucagon-like peptide 2 (GLP-2) and intestinal inflammation is unclear. GLP-2 promotes mucosal growth, decreases permeability and reduces inflammation in the intestine; physiological stimulation of GLP-2 release is triggered by nutrient contact. The authors hypothesized that ileal Crohn disease (CD) affects GLP-2 release.METHODS: With ethics board approval, pediatric patients hospitalized with CD were studied; controls were recruited from local schools. Inclusion criteria were endoscopy-confirmed CD (primarily of the small intestine) with a disease activity index >150. Fasting and postprandial GLP-2 levels and quantitative urinary recovery of orally administered 3-O-methyl-glucose (active transport) and lactulose⁄mannitol (passive) were quantified during the acute and remission phases.RESULTS: Seven patients (mean [± SD] age 15.3 ± 1.3 years) and 10 controls (10.3 ± 1.6 years) were studied. In patients with active disease, fasting levels of GLP-2 remained stable but postprandial levels were reduced. Patients with active disease exhibited reduced glucose absorption and increased lactulose⁄mannitol recovery; all normalized with disease remission. The change in the lactulose⁄mannitol ratio was due to both reduced lactulose and increased mannitol absorption.CONCLUSIONS: These findings suggest that pediatric patients with acute ileal CD have decreased postprandial GLP-2 release, reduced glucose absorption and increased intestinal permeability. Healing of CD resulted in normalization of postprandial GLP-2 release and mucosal functioning (nutrient absorption and permeability), the latter due to an increase in mucosal surface area. These findings have implications for the use of GLP-2 and feeding strategies as a therapy in CD patients; further studies of the effects of inflammation and the GLP-2 axis are recommended.",
keywords = "3-O-Methylglucose, Adolescent, Child, Crohn Disease, Female, Glucagon-Like Peptide 2, Humans, Intestinal Absorption, Intestine, Small, Lactulose, Longitudinal Studies, Male, Mannitol, Pilot Projects, Postprandial Period, Signal Transduction",
author = "Sigalet, {David L} and Dragan Kravarusic and Decker Butzner and Bolette Hartmann and Holst, {Jens Juul} and Jon Meddings",
year = "2013",
month = oct,
language = "English",
volume = "27",
pages = "587--92",
journal = "Canadian Journal of Gastroenterology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients

AU - Sigalet, David L

AU - Kravarusic, Dragan

AU - Butzner, Decker

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Meddings, Jon

PY - 2013/10

Y1 - 2013/10

N2 -  BACKGROUND⁄/OBJECTIVES: The relationship between the enteroendocrine hormone glucagon-like peptide 2 (GLP-2) and intestinal inflammation is unclear. GLP-2 promotes mucosal growth, decreases permeability and reduces inflammation in the intestine; physiological stimulation of GLP-2 release is triggered by nutrient contact. The authors hypothesized that ileal Crohn disease (CD) affects GLP-2 release.METHODS: With ethics board approval, pediatric patients hospitalized with CD were studied; controls were recruited from local schools. Inclusion criteria were endoscopy-confirmed CD (primarily of the small intestine) with a disease activity index >150. Fasting and postprandial GLP-2 levels and quantitative urinary recovery of orally administered 3-O-methyl-glucose (active transport) and lactulose⁄mannitol (passive) were quantified during the acute and remission phases.RESULTS: Seven patients (mean [± SD] age 15.3 ± 1.3 years) and 10 controls (10.3 ± 1.6 years) were studied. In patients with active disease, fasting levels of GLP-2 remained stable but postprandial levels were reduced. Patients with active disease exhibited reduced glucose absorption and increased lactulose⁄mannitol recovery; all normalized with disease remission. The change in the lactulose⁄mannitol ratio was due to both reduced lactulose and increased mannitol absorption.CONCLUSIONS: These findings suggest that pediatric patients with acute ileal CD have decreased postprandial GLP-2 release, reduced glucose absorption and increased intestinal permeability. Healing of CD resulted in normalization of postprandial GLP-2 release and mucosal functioning (nutrient absorption and permeability), the latter due to an increase in mucosal surface area. These findings have implications for the use of GLP-2 and feeding strategies as a therapy in CD patients; further studies of the effects of inflammation and the GLP-2 axis are recommended.

AB -  BACKGROUND⁄/OBJECTIVES: The relationship between the enteroendocrine hormone glucagon-like peptide 2 (GLP-2) and intestinal inflammation is unclear. GLP-2 promotes mucosal growth, decreases permeability and reduces inflammation in the intestine; physiological stimulation of GLP-2 release is triggered by nutrient contact. The authors hypothesized that ileal Crohn disease (CD) affects GLP-2 release.METHODS: With ethics board approval, pediatric patients hospitalized with CD were studied; controls were recruited from local schools. Inclusion criteria were endoscopy-confirmed CD (primarily of the small intestine) with a disease activity index >150. Fasting and postprandial GLP-2 levels and quantitative urinary recovery of orally administered 3-O-methyl-glucose (active transport) and lactulose⁄mannitol (passive) were quantified during the acute and remission phases.RESULTS: Seven patients (mean [± SD] age 15.3 ± 1.3 years) and 10 controls (10.3 ± 1.6 years) were studied. In patients with active disease, fasting levels of GLP-2 remained stable but postprandial levels were reduced. Patients with active disease exhibited reduced glucose absorption and increased lactulose⁄mannitol recovery; all normalized with disease remission. The change in the lactulose⁄mannitol ratio was due to both reduced lactulose and increased mannitol absorption.CONCLUSIONS: These findings suggest that pediatric patients with acute ileal CD have decreased postprandial GLP-2 release, reduced glucose absorption and increased intestinal permeability. Healing of CD resulted in normalization of postprandial GLP-2 release and mucosal functioning (nutrient absorption and permeability), the latter due to an increase in mucosal surface area. These findings have implications for the use of GLP-2 and feeding strategies as a therapy in CD patients; further studies of the effects of inflammation and the GLP-2 axis are recommended.

KW - 3-O-Methylglucose

KW - Adolescent

KW - Child

KW - Crohn Disease

KW - Female

KW - Glucagon-Like Peptide 2

KW - Humans

KW - Intestinal Absorption

KW - Intestine, Small

KW - Lactulose

KW - Longitudinal Studies

KW - Male

KW - Mannitol

KW - Pilot Projects

KW - Postprandial Period

KW - Signal Transduction

M3 - Journal article

C2 - 24106731

VL - 27

SP - 587

EP - 592

JO - Canadian Journal of Gastroenterology

JF - Canadian Journal of Gastroenterology

SN - 2291-2789

IS - 10

ER -

ID: 117853262